UEG Journal UEG Journal
-
- Health & Fitness
Podcast feed from the UEG Journal, the official journal from the United European Gastroenterology
-
Gallstone Disease Relapse: Insights from the RELAPSTONE Study
In this episode, Ahsen Ustaoglu interviews Dr Raul Velamazan to discuss their findings from the multicentre RELAPSTONE study on recurrence patterns and risk factors for relapse after first admission of patients with symptomatic gallstone disease
-
Toward a more precise prognostic stratification in acute decompensation of cirrhosis: The Padua model 2.0.
Dr. Tarik Kani interviews Dr Alberto Zanetto from Italy, on their study which they were created a new model to predict acute-on-chronic liver failure in decompensated cirrhosis.
-
Effect of miR-10b in regulating gut barrier dysfunction in diabetes and GI dysmotility
Dr Ahsen Ustaoglu interviews Dr Rajan Singh and Dr Hannah Zogg from the University of Nevada, USA, on their study which investigated the role of microRNA 10b-5p in regulating gut barrier function in an in vivo model of diabetes and gastrointestinal dysmotility, important mechanistic work in the field of Neurogastroenterology.
-
Interactive Insights With Your UEG Podcast Hosts: UEGW Special
In this December special episode, your UEG Journal podcast hosts H. Tarik Kani and Ahsen Ustaoglu are joined by UEG Talks podcast hosts Egle Dieninyte and Pradeep Mundre in hosting very special guests at UEG Week 2023 in Copenhagen. You can expect to hear important insights from Dr Enrique de Madaria and UEG Journal Editor-in-Chief Prof Joost Drenth, as well as Young GIs.
-
Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship
Dr. H. Tarik Kani talks to Dr. Anouk Wijnands (Netherlands) about her multicenter cohort study that investigated the relationship between smoking and colorectal neoplasia in patients with Inflammatory Bowel Disease with a 10-year follow-up.
-
The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program
Dr Ahsen Ustaoglu interviews Dr Iris Levink on her study investigating the additive value of CA19.9 monitoring in a pancreatic cyst surveillance program, part of the PACYFIC-trial (www.pacyfic.net).